Karuna Therapeutics’ KarXT results in schizophrenia published in The Lancet

Karuna Therapeutics announced that results from the Phase 3 EMERGENT-2 trial of KarXT in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive and negative symptoms of schizophrenia among adult patients experiencing acute psychosis, alongside a distinct tolerability profile. In the trial, KarXT demonstrated a statistically significant and clinically meaningful 9.6-point reduction in Positive and Negative Syndrome Scale total score compared to placebo at week 5, the primary outcome measure of the study. KarXT demonstrated statistically significant reductions compared to placebo at week 5 on each secondary endpoint. KarXT was generally well tolerated, with overall discontinuation rates similar to placebo. Discontinuation rates due to treatment-emergent adverse events were also similar between KarXT and placebo. The most common KarXT TEAEs were constipation, dyspepsia, nausea, vomiting, hypertension, dizziness, and gastroesophageal reflux disease. The majority of common TEAEs occurred in the first two to three weeks of treatment, were transient, and resolved before the end of the trial. It was not associated with many of the adverse events typically associated with current antipsychotic treatments, including somnolence, weight gain and extrapyramidal motor symptoms.